Fulvestrant: A further treatment option for patients with metastatic uterine cancer?

Onkologie

Volumn 29, Issue 12, 2006, Pages 577-580

  Lux, M P ^a   Wenkel, E M ^a   Beckmann, K ^a   Beckmann, M W ^a   Thiel, F ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Endocrine therapy; Fulvestrant; Hepatic metastases; Uterine cancer, advanced

Indexed keywords

DOCETAXEL; FULVESTRANT;

ADULT; ADVANCED CANCER; ARTICLE; BLADDER METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SIZE; CASE REPORT; CLINICAL FEATURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; QUALITY OF LIFE; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UTERUS CANCER; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; ESTRADIOL; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UTERINE NEOPLASMS;

EID: 33845799161     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096541     Document Type: Article

References (31)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. DiSaia PJ, Creasman WT: Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy. Clin Obstet Gynaecol 1986;13:751-765.
3. Elit L, Hirte H: Novel strategies for systemic treatment of endometrial cancer. Expert Opin Investig Drugs 2000;9:2831-2853.
4. National Comprehensive Cancer Network: Uterine Cancers. Clinical Practice Guidelines in Oncology v.1.2006. www.nccn.org/professionals/physician_gls/PDF/ uterine.pdf.
5. Hanf V, Gunthert AR, Emons G: Endometrial cancer. Onkologie 2003;26:429-436.
6. Kneale BL: Adjunctive and therapeutic progestins in endometrial cancer. Clin Obstet Gynaecol 1986;13:789-809.
7. Podratz KC: Hormonal therapy in endometrial carcinoma. Recent Results Cancer Res 1990;118:242-251.
8. Chan S: A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin Oncol 2002;29:129-133.
9. Gadducci A, Cosio S, Genazzani AR: Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs 2004;5:1031-1044.
10. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-238.
11. Günthert AR, Ackermann S, Kiesel L, Steiner E, Schröder W, Camara O, Mallman P, Emons G: Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer, AGO Uterus-4. J Clin Oncol (Meeting Abstracts) 2005;23:abstr 5083.
12. Carter J, Pather S: An overview of uterine cancer and its management. Expert Rev Anticancer Ther 2006;6:33-42.
13. Baekelandt M: Hormonal treatment of endometrial carcinoma. Expert Rev Anticancer Ther 2002;2:106-112.
14. Munster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C: Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 2001;19:2002-2009.
15. Dardes RC, Bentrem D, O'Regan RM, Schafer JM, Jordan VC: Effects of the new selective estrogen receptor modulator LY353381.HCl (arzoxifene) on human endometrial cancer growth in athymic mice. Clin Cancer Res 2001;7:4149-4155.
16. Litherland S, Jackson IM: Antiestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 1988;15:183-194.
17. McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T, Bloss J, Sabbatini P: A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 2003;90:64-69.
18. Heyer H, Ohlinger R, Arndt D, Belau A, Nehmzow M, Hosten N, Kohler G: Selective pretreatment diagnostic imaging for detecting remote metastases in patients with endometrial cancer. Onkologie 2006;29:85-89.
19. Davila E, Vogel CL, East D, Cairns V, Hilsenbeck S: Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer 1988;61:2161-2167.
20. Medroxyprogesterone and palliative care: new indication. No impact on quality of life. Prescrire Int 2001;10:3-4.
21. Brema F, Queirolo MA, Canobbio L, Bruzzi P, Puntoni R, Campora E, Rosso R: Hematologic parameters during treatment with high-dose medroxyprogesterone acetate. Tumori 1981;67:125-128.
22. Quinn MA: Hormonal treatment of endometrial cancer. Hematol Oncol Clin North Am 1999;13:163-187.
23. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J: Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol 1991;9:1740-1748.
24. Mourits MJ, de Vries EG, Willemse PH, Ten Hoor KA, Hollema H, van der Zee AG: Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001;97:855-866.
25. Van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
26. Addo S, Yates RA, Laight A: A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002;87:1354-1359.
27. Dukes M, Miller D, Wakeling AE, Waterton JC: Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 1992;135:239-247.
28. O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R, Jordan VC: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1998;90:1552-1558.
29. Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-1613.
30. Dodwell D: Time to response - a comparison of fulvestrant with anastrozole. Eur Jour Cancer Suppl 2005;3:79(abstr 280).
31. Hoffman MA, Khan A: Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex®) after prior progestin and anastrozole therapy. Gynecol Oncol 2006;100:439-441.